Prospects for effective treatment of AL amyloidosis?

QJM - Monthly Journal of the Association of Physicians

Volumn 93, Issue 5, 2000, Pages 257-260

  Iggo, N ^a   Littlewood, T ^b   Winearls, C G ^b  

^a ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4' IODOESORUBICIN; ALKALINE PHOSPHATASE; ALKYLATING AGENT; AMYLOID; AMYLOID A PROTEIN; AMYLOID P COMPONENT; AMYLOID PRECURSOR PROTEIN; BETA 2 MICROGLOBULIN; CHLORAMBUCIL; COLCHICINE; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; DOXORUBICIN DERIVATIVE; GLYCOPROTEIN; IMMUNOGLOBULIN LIGHT CHAIN; IODINE 123; MELPHALAN; PARAPROTEIN; PLACEBO; PREALBUMIN; PREDNISOLONE; SERUM AMYLOID P; VINCRISTINE;

ALPHA CHAIN DISEASE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HALF LIFE; DRUG MEGADOSE; EDITORIAL; HEMODIALYSIS; HUMAN; HUMAN TISSUE; JUVENILE RHEUMATOID ARTHRITIS; LEUKEMIA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; MOUSE; MULTIPLE MYELOMA; MULTIPLE ORGAN FAILURE; MYELODYSPLASIA; NONHUMAN; ORGAN TRANSPLANTATION; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; SCINTIGRAPHY; SURVIVAL RATE; WHOLE BODY RADIATION;

EID: 0034020766     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/93.5.257     Document Type: Editorial

References (30)

1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. New Engl J Med 1997; 337:898-909.
2. Hawkins PN. Diagnosis and monitoring of amyloidosis. Baillieres Clin Rheumatol 1994; 8:635-59.
3. Hawkins PN, Richardson S, Vigushin DM, et al. Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis. Arthritis Rheum 1993; 36:842-51.
4. Savolainen HA. Chlorambucil in severe juvenile chronic arthritis; longterm followup with special reference to amyloidosis. J Rheumatol 1999; 26:896-903.
5. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986; 314:1001-5.
6. Tan S, Irish A, VVinearls CG, et al. Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. Kidney Int 1996; 50:282-9.
7. Holmgren G, Ericzon B, Groth C, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet!993; 341:1113-16.
8. Jones NM, Hilton PJ, Tighe JR, Hobbs JR. Treatment of 'primary' renal amyloidosis with melphalan. Lancet 1972; 2:616-19.
9. Cohen HJ, Lessin LS, Hallal J, Burkholder P. Resolution of primary amyloidosis during chemotherapy. Studies in a patient with nephrotic syndrome. Ann Intern Med 1975; 82:466-73.
10. Horne MK. Letter: Improvement in amyloidosis. Ann Intern Med 1975; 83:281-2.
11. Gertz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood 1991; 77:257-62.
12. Kyle RA, Greipp PR. Primary systemic amyloidosis: Comparison of melphalan and prednisolone versus placebo. Blood 1978; 52:818-27.
13. Brandwein SR, Sipe JD, Skinner M, Cohen AS. Effect of colchicine on experimental amyloidosis in two CBA/J mouse models. Chronic inflammatory stimulation and administration of amyloid-enhancing factor during acute inflammation. Lab Invest 1985; 52:319-25.
14. Cohen AS, Rubinow A, Anderson JJ, et al. Survival of patients with primary (AL) amyloidosis. Colchicine-treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973). Am J Med 1987; 82:1182-90.
15. Skinner M, Anderson J, Simms R, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am JMed, 100:290-8.
16. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Vfec 1997; 336:1202-7.
17. Levy Y, Belghiti Deprez D, Sobel A. [Treatment of AL amyloidosis without myeloma]. Ann Med Interne Paris 1988; 139:190-3.
18. Van Eygen K, Zachee P, Maertens J, et al. Treatment of primary amyloidosis with VAD combination chemotherapy results in improved survival. Blood 1996; 88(Suppl.1 ):591a[Abstract].
19. Gertz MA, Lacy MQ, Lust JA, Griepp PR, Witzig TE, Kyle RA. Prospective randomised trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol 1999; 17:262-7.
20. Gianni L, Bellotti V, Gianni AM, Merlini G. New drug therapy of amyloidoses: resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin. Blood 1995; 86:855-61.
21. Merlini G, Ascari E, Amboldi N, etal. Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci USA 1995; 92:2959-63.
22. Jagannath S, Tricot G, Barlogie B. Autotransplants in multiple myeloma: Pushing the envelope. Hematol Oncol Clin North'Am 1997; 11:363-81.
23. van Buren M, Hene RJ, Verdonck LF, Verzijlbergen FJ, Lokhorst HM. Clinical remission after syngeneic bone marrow transplantation in a patient with AL amyloidosis. Ann Intern Med 1 995; 122:508-10.
24. Comenzo RL, Vosburgh E, Falk RH, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998; 91:3662-70.
25. Moreau P, Leblond V, Bourquelot P, et al. Prognostic factors for survival and response after high dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. BrJ Haematol 1998; 101:766-9.
26. Saba N, Sutton DM, Ross HJ, et al. High treatment related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplantation 1999; 24:853-5.
27. Comenzo RL, Sanchorawala V, Fisher C, et al. Intermediate- dose intravenous melphalan and blood stem cells mobilised with sequential GM +G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br. J. Haematol 1999; 104:553-9.
28. Gazitt Y, Reading CC, Hoffman R, etal. Purified CD34 + Lin- Thy + stem cells do not contain clonal myeloma cells. Blood 1995; 86:381-9.
29. Comenzo RL, Michelle D, LeBlanc M, et al. Mobilized CD34+ cells selected as autografts in patients with primary light-chain amyloidosis: rationale and application. Transfusion 1998; 38:60-9.
30. Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89:789-93.